PubRank

Roman Hajek

Author PubWeight™ 64.99‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012 5.16
2 Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007 3.54
3 Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011 3.07
4 Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 2008 2.12
5 Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2012 2.01
6 Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol 2013 1.99
7 European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica 2014 1.57
8 International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol 2014 1.52
9 TGF-β - an excellent servant but a bad master. J Transl Med 2012 1.41
10 Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol 2010 1.38
11 Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica 2013 1.22
12 Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Br J Haematol 2010 1.20
13 Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer 2008 1.13
14 Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. J Clin Oncol 2012 1.10
15 Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PLoS One 2012 1.09
16 Dendritic cell vaccines in the treatment of multiple myeloma: advances and limitations. Med Oncol 2002 1.08
17 Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial. Leuk Lymphoma 2011 0.96
18 Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res 2013 0.94
19 Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma. Leuk Lymphoma 2012 0.92
20 Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma. J Cell Mol Med 2014 0.92
21 Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial. Leuk Lymphoma 2013 0.91
22 Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response. Ann Hematol 2009 0.90
23 Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients. Hematol Oncol 2012 0.90
24 Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica 2013 0.89
25 Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: a cause for immune impairment. PLoS One 2012 0.88
26 Serum miR-29a as a marker of multiple myeloma. Leuk Lymphoma 2012 0.88
27 Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients. Haematologica 2011 0.87
28 Mechanism of immunomodulatory drugs in multiple myeloma. Leuk Res 2012 0.86
29 MyelomA Genetics International Consortium. Leuk Lymphoma 2012 0.86
30 Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy. Biol Blood Marrow Transplant 2010 0.86
31 Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma. Haematologica 2010 0.85
32 Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma 2008 0.85
33 Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma 2009 0.84
34 Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Haematologica 2011 0.84
35 Flow cytometry based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment. Cytometry B Clin Cytom 2013 0.83
36 Proteomic analysis in multiple myeloma research. Mol Biotechnol 2011 0.83
37 Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib. Clin Lymphoma Myeloma Leuk 2013 0.82
38 Comparison of functional fibrinogen assessment using thromboelastography with the standard von Clauss method. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2011 0.81
39 Interdigitating dendritic cell sarcoma of the leg. Onkologie 2009 0.81
40 Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse. Clin Lymphoma Myeloma 2009 0.80
41 Molecular heterogeneity and centrosome-associated genes in multiple myeloma. Leuk Lymphoma 2013 0.79
42 Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome. Clin Lymphoma Myeloma Leuk 2011 0.79
43 Detection and long-term in vivo monitoring of individual tumor-specific T cell clones in patients with metastatic melanoma. J Immunol 2007 0.79
44 Flow cytometry-based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment. Cytometry B Clin Cytom 2013 0.78
45 Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma. J Transl Med 2013 0.78
46 Shared structural features of the 9aaTAD family in complex with CBP. Mol Biosyst 2015 0.78
47 Bone marrow plasma cell separation - validation of separation algorithm. Clin Chem Lab Med 2012 0.78
48 Generation of antigen-loaded dendritic cells in a serum-free medium using different cytokine combinations. Vaccine 2003 0.78
49 Results of therapy and changing prognosis of multiple myeloma during the last 40 years in the region of North and Middle Moravia: group of 562 patients. Hematol J 2003 0.77
50 1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens. Leuk Lymphoma 2012 0.77
51 Dendritic cell-based immunotherapy for the treatment of hematological malignancies. Hematology 2003 0.77
52 Combination of serum microRNA-320a and microRNA-320b as a marker for Waldenström macroglobulinemia. Am J Hematol 2015 0.77
53 Association of aneuploidy category with centrosome amplification in multiple myeloma. Leuk Lymphoma 2011 0.77
54 10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group. Leuk Res 2013 0.77
55 Contribution of regulatory T cells to immunosuppression and disease progression in multiple myeloma patients. Oncoimmunology 2013 0.77
56 Skin lesions induced by bortezomib. Haematologica 2005 0.77
57 Nestin expression throughout multistep pathogenesis of multiple myeloma. Br J Haematol 2013 0.76
58 Outcome of patients with multiple myeloma and hypertension treated with angiotensin-I-converting enzyme inhibitors during high-dose chemotherapy. Hematol J 2005 0.76
59 Individual myeloma-specific T-cell clones eliminate tumour cells and correlate with clinical outcomes in patients with multiple myeloma. Br J Haematol 2010 0.76
60 Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia. Genomics 2013 0.76
61 Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide. Clin Lymphoma Myeloma Leuk 2011 0.76
62 Sequential bypass grafting on the beating heart: blood flow characteristics. Ann Thorac Surg 2006 0.75
63 Bone marrow plasma cell separation - validation of separation algorithm. Clin Chem Lab Med 2012 0.75
64 Salvage treatment with upfront melphalan 100 mg/m(2) and consolidation with novel drugs for fulminant progression of multiple myeloma. Ann Hematol 2009 0.75
65 Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma. Ann Hematol 2011 0.75
66 Accidental deep hypothermia with cardiac arrest. Prompt complete recovery after rewarming by extracorporeal circulation. Case report. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2007 0.75
67 Measurement of the flow in coronary artery bypass grafts. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2006 0.75
68 Vacuum-assisted closure in the treatment of sternal wound infection after cardiac surgery. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2007 0.75